KMDS
E-submission
Search
- Page Path
- HOME > Search
Case Reports
- Suppression of Myoclonus in Corticobasal Degeneration by Levetiracetam
- Jae Wook Cho, Jae Hyeok Lee
- J Mov Disord. 2014;7(1):28-30. Published online April 30, 2014
- DOI: https://doi.org/10.14802/jmd.14007
- 10,544 View
- 103 Download
- 12 Web of Science
- 11 Crossref
-
Abstract
PDF - Myoclonus in corticobasal degeneration (CBD) has often been associated with severe and difficult to treat disabilities. Levetiracetam is a new antiepileptic agent with antimyoclonic effects. Herein, we present a 72-year-old woman with clinically probable CBD and with spontaneous rhythmic myoclonus in the right foot, which was markedly ameliorated through treatment with levetiracetam. The effect of levetiracetam was associated with the decreased amplitude of enlarged cortical somatosensory evoked potentials. This result suggests that the antimyoclonic effect of levetiracetam might be mediated through the suppression of increased cortical excitability.
-
Citations
Citations to this article as recorded by
- Management Strategies for Atypical Parkinsonism
Vasilios C. Constantinides, Nikolaos Giagkou, Maria-Evgenia Brinia, Christos Koros, Leonidas Stefanis, Maria Stamelou
Current Treatment Options in Neurology.2024; 26(5): 169. CrossRef - Chinese nutraceuticals and physical activity; their role in neurodegenerative tauopathies
Abdullahi Alausa, Sunday Ogundepo, Barakat Olaleke, Rofiat Adeyemi, Mercy Olatinwo, Aminat Ismail
Chinese Medicine.2021;[Epub] CrossRef - Four-Repeat Tauopathies: Current Management and Future Treatments
Lawren VandeVrede, Peter A. Ljubenkov, Julio C. Rojas, Ariane E. Welch, Adam L. Boxer
Neurotherapeutics.2020; 17(4): 1563. CrossRef - Physiology-Based Treatment of Myoclonus
Ashley B. Pena, John N. Caviness
Neurotherapeutics.2020; 17(4): 1665. CrossRef - Pharmacological interventions in corticobasal degeneration: a review
Leonardo Caixeta, Victor de Melo Caixeta, Yanley Lucio Nogueira, Tales Alexandre Aversi-Ferreira
Dementia & Neuropsychologia.2020; 14(3): 243. CrossRef - Available and future treatments for atypical parkinsonism. A systematic review
Davide Vito Moretti
CNS Neuroscience & Therapeutics.2019; 25(2): 159. CrossRef - An Update on Myoclonus Management
Christine M. Stahl, Steven J. Frucht
Expert Review of Neurotherapeutics.2019; 19(4): 325. CrossRef - Corticobasal degeneration: key emerging issues
F. Ali, K. A. Josephs
Journal of Neurology.2018; 265(2): 439. CrossRef - Focal Predominant Forms of Posthypoxic Action Myoclonus
Carmen Gasca‐Salas, Anthony E. Lang
Movement Disorders Clinical Practice.2016; 3(4): 417. CrossRef - Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options
Ruth Lamb, Jonathan D. Rohrer, Andrew J. Lees, Huw R. Morris
Current Treatment Options in Neurology.2016;[Epub] CrossRef - An Update and Review of the Treatment of Myoclonus
Kelly Mills, Zoltan Mari
Current Neurology and Neuroscience Reports.2015;[Epub] CrossRef
- Management Strategies for Atypical Parkinsonism
- Neuroleptic Malignant Syndrome in a Patient with Corticobasal Degeneration
- Myung Jun Lee, Chul Hyoung Lyoo, Myung Sik Lee
- J Mov Disord. 2011;4(2):73-74.
- DOI: https://doi.org/10.14802/jmd.11015
- 10,183 View
- 53 Download
-
Abstract
PDF
Parkinson’s disease is a principal underlying disease of neuroleptic malignant syndrome (NMS) occurring in parkinsonian disorders, but NMS may occur in patients with progressive supranuclear palsy and multiple system atrophy. We report first patient with corticobasal degeneration (CBD) who developed NMS after abrupt reduction of antiparkinsonian medication and concurrent infection. It should be kept in mind that the prevention of infectious illness, which is common complication in parkinson-plus syndrome, is important, and dose reduction or withdrawal of anti-parkinsonian medications should be carefully performed even in the patients with CBD who are expected to be unresponsive to levodopa treatment.
First
Prev
